Archive, page 6
Source-linked news on obesity medications and weight-loss surgery.
Search the news archive
Explore: Insurance · Safety · Revision surgery
Older briefs
Page 6
-
Review finds less urinary leakage after bariatric surgery
A meta-analysis of 32 prospective studies and 5,299 participants found less urinary incontinence and improved prolapse symptoms after bariatric surgery.
-
Small study finds no disproportionate muscle loss with GLP‑1 weight loss
Mouse experiments and a 10-person, 12-week semaglutide pilot found fat loss exceeded skeletal-muscle change and measured strength did not decline.
-
FDA approves weekly Wegovy HD 7.2 mg for adults needing additional weight reduction
FDA authorized the weekly 7.2 mg semaglutide injection Wegovy HD on March 19, 2026.
-
Small heart‑failure study reports weight loss, but procedural risk remains uncertain
In a two-center retrospective cohort, 41 of 1,678 metabolic and bariatric procedures involved adults with heart failure.
-
Experts propose shared definitions for weight regain after bariatric surgery
A modified Delphi project developed shared terms and thresholds for assessing suboptimal response after metabolic and bariatric surgery.
-
FDA sends 30 telehealth companies warning letters over compounded GLP‑1 claims
FDA said 30 telehealth companies used false or misleading website claims for compounded GLP-1 products.
-
Obesity Society cites an uncharacterized impurity in compounded tirzepatide and B12 products
The Obesity Society called for stronger oversight after a report found an impurity in tested compounded tirzepatide and vitamin B12 combinations.
-
ZUPREME‑1 topline results report up to 10.7% mean weight loss with petrelintide
Sponsor-reported phase 2 results showed up to 10.7% average weight loss at 42 weeks with investigational petrelintide, versus 1.7% with placebo.
-
Small review finds weight loss after bariatric surgery in people with low muscle mass
Seven studies involving 1,704 patients found weight and BMI reductions among people classified with sarcopenic obesity, but inconsistent definitions and imprecise safety estimates limit the conclusions.
-
Review finds uncertain benefit from GLP‑1 use before bariatric surgery
A 10-study meta-analysis linked preoperative GLP-1 use with modest weight reduction before surgery, but found no clear improvement in later weight loss, complications, or assessed comorbidities.
-
Review finds no clear link between PTSD before surgery and later weight loss
None of the four studies that measured it found a clear association between PTSD and weight loss after bariatric surgery, but the evidence was limited and mental health quality of life may still be worse.
-
Short digital prompts improve short‑term plans for healthier habits during GLP‑1 treatment
An online trial of 5,054 adults taking GLP-1 medicines found that one set of written prompts plus a short video raised what people expected to do about diet, movement, stress and sleep. The effect had shrunk by two weeks, and only one self-reported behavior differed.
-
Tirzepatide trial subgroup lost weight after starting medicines linked with weight gain
A post hoc analysis of three SURMOUNT trials found sizable treatment differences among participants who started medicines associated with weight gain, but the subgroup was not randomized around those added drugs.
About this publication
Reporting standards and transparency
How we report
Obesity Treatment News is a BariatricPal publication. We review the linked source material, explain what changed, and state what the evidence does not establish.
Corrections
Send factual corrections through Contact BariatricPal. Material corrections are dated and noted in the article.
Ownership and commerce
BariatricPal owns OTN and the BariatricPal Store. Pages may include clearly separated advertising or store links. Commerce does not change the source summary.
About BariatricPal · Brief author · Contact · Weight-loss medications · Weight-loss surgery